Cargando…

Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis

OBJECTIVES: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for revascularising coronary arteries in patients with chronic kidney disease (CKD) and end‐stage renal disease (ESRD). CKD is described as a continuous decrease in the glomerular filtration ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xihui, Xiao, Feng, Zhang, Siyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596450/
https://www.ncbi.nlm.nih.gov/pubmed/34117687
http://dx.doi.org/10.1111/ijcp.14506
_version_ 1784600382070063104
author Li, Xihui
Xiao, Feng
Zhang, Siyu
author_facet Li, Xihui
Xiao, Feng
Zhang, Siyu
author_sort Li, Xihui
collection PubMed
description OBJECTIVES: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for revascularising coronary arteries in patients with chronic kidney disease (CKD) and end‐stage renal disease (ESRD). CKD is described as a continuous decrease in the glomerular filtration rate or abnormalities in kidney structure or function. METHODS: PubMed, Cochrane Library and Embase databases were searched for studies on the revascularisation of coronary arteries in patients with CKD and ESRD. RESULTS: Since no randomised controlled trials (RCTs) have addressed this issue so far, 31 observational studies involving 74 805 patients were included in this meta‐analysis. Compared with PCI, patients undergoing CABG have significantly higher early mortality (CKD: RR = 1.62, 95% CI: 1.17‐2.25, pheterogeneity = 0.476, I (2) = 0; ESRD: RR = 1.99, 95% CI: 1.46‐2.71, pheterogeneity = 0.001, I (2) = 66.9%). Patients with ESRD undergoing CABG have significantly lower all‐cause mortality (RR = 0.95, 95% CI: 0.93‐0.96, pheterogeneity < 0.001, I (2) = 82.9%) and cardiac mortality (RR = 0.73, 95% CI: 0.58‐0.92, pheterogeneity = 0.908, I (2) = 0). The long‐term risk of repeat revascularisation (CKD: RR = 0.24, 95% CI: 0.19‐0.30, pheterogeneity = 0.489, I (2) = 0; ESRD: RR = 0.23, 95% CI: 0.15‐0.34, pheterogeneity = 0.012, I (2) = 54.4%) and myocardial infarction (CKD: RR = .57, 95% CI: 0.38‐0.85, pheterogeneity = 0.025, I (2) = 49.9%; ESRD: RR = 0.42, 95% CI: 0.40‐0.44, pheterogeneity = 0.49, I (2) = 0) remained significantly higher in the PCI group. CONCLUSIONS: Patients with ESRD, but not CKD, who underwent CABG had significantly lower all‐cause mortality and cardiac mortality. However, CABG was associated with an increased risk of early mortality in patients with CKD or ESRD. Adequately powered, contemporary, prospective RCTs are needed to define the optimal revascularisation strategy for patients with CKD and ESRD.
format Online
Article
Text
id pubmed-8596450
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85964502021-11-22 Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis Li, Xihui Xiao, Feng Zhang, Siyu Int J Clin Pract Meta‐analysis OBJECTIVES: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for revascularising coronary arteries in patients with chronic kidney disease (CKD) and end‐stage renal disease (ESRD). CKD is described as a continuous decrease in the glomerular filtration rate or abnormalities in kidney structure or function. METHODS: PubMed, Cochrane Library and Embase databases were searched for studies on the revascularisation of coronary arteries in patients with CKD and ESRD. RESULTS: Since no randomised controlled trials (RCTs) have addressed this issue so far, 31 observational studies involving 74 805 patients were included in this meta‐analysis. Compared with PCI, patients undergoing CABG have significantly higher early mortality (CKD: RR = 1.62, 95% CI: 1.17‐2.25, pheterogeneity = 0.476, I (2) = 0; ESRD: RR = 1.99, 95% CI: 1.46‐2.71, pheterogeneity = 0.001, I (2) = 66.9%). Patients with ESRD undergoing CABG have significantly lower all‐cause mortality (RR = 0.95, 95% CI: 0.93‐0.96, pheterogeneity < 0.001, I (2) = 82.9%) and cardiac mortality (RR = 0.73, 95% CI: 0.58‐0.92, pheterogeneity = 0.908, I (2) = 0). The long‐term risk of repeat revascularisation (CKD: RR = 0.24, 95% CI: 0.19‐0.30, pheterogeneity = 0.489, I (2) = 0; ESRD: RR = 0.23, 95% CI: 0.15‐0.34, pheterogeneity = 0.012, I (2) = 54.4%) and myocardial infarction (CKD: RR = .57, 95% CI: 0.38‐0.85, pheterogeneity = 0.025, I (2) = 49.9%; ESRD: RR = 0.42, 95% CI: 0.40‐0.44, pheterogeneity = 0.49, I (2) = 0) remained significantly higher in the PCI group. CONCLUSIONS: Patients with ESRD, but not CKD, who underwent CABG had significantly lower all‐cause mortality and cardiac mortality. However, CABG was associated with an increased risk of early mortality in patients with CKD or ESRD. Adequately powered, contemporary, prospective RCTs are needed to define the optimal revascularisation strategy for patients with CKD and ESRD. John Wiley and Sons Inc. 2021-06-29 2021-11 /pmc/articles/PMC8596450/ /pubmed/34117687 http://dx.doi.org/10.1111/ijcp.14506 Text en © 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Meta‐analysis
Li, Xihui
Xiao, Feng
Zhang, Siyu
Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
title Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
title_full Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
title_fullStr Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
title_full_unstemmed Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
title_short Coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: A meta‐analysis
title_sort coronary revascularisation in patients with chronic kidney disease and end‐stage renal disease: a meta‐analysis
topic Meta‐analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596450/
https://www.ncbi.nlm.nih.gov/pubmed/34117687
http://dx.doi.org/10.1111/ijcp.14506
work_keys_str_mv AT lixihui coronaryrevascularisationinpatientswithchronickidneydiseaseandendstagerenaldiseaseametaanalysis
AT xiaofeng coronaryrevascularisationinpatientswithchronickidneydiseaseandendstagerenaldiseaseametaanalysis
AT zhangsiyu coronaryrevascularisationinpatientswithchronickidneydiseaseandendstagerenaldiseaseametaanalysis